These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 21228032)

  • 1. Deep sequencing reveals double mutations in cis of MPL exon 10 in myeloproliferative neoplasms.
    Pietra D; Brisci A; Rumi E; Boggi S; Elena C; Pietrelli A; Bordoni R; Ferrari M; Passamonti F; De Bellis G; Cremonesi L; Cazzola M
    Haematologica; 2011 Apr; 96(4):607-11. PubMed ID: 21228032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms.
    Milosevic Feenstra JD; Nivarthi H; Gisslinger H; Leroy E; Rumi E; Chachoua I; Bagienski K; Kubesova B; Pietra D; Gisslinger B; Milanesi C; Jäger R; Chen D; Berg T; Schalling M; Schuster M; Bock C; Constantinescu SN; Cazzola M; Kralovics R
    Blood; 2016 Jan; 127(3):325-32. PubMed ID: 26423830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. JAK2 and MPL gene mutations in V617F-negative myeloproliferative neoplasms.
    Siemiatkowska A; Bieniaszewska M; Hellmann A; Limon J
    Leuk Res; 2010 Mar; 34(3):387-9. PubMed ID: 19643476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low
    Makarik TV; Abdullaev AO; Nikulina EE; Treglazova SA; Stepanova EE; Subortseva IN; Kovrigina AM; Melikyan AL; Kulikov SM; Sudarikov AB
    Genes (Basel); 2021 Apr; 12(4):. PubMed ID: 33921387
    [No Abstract]   [Full Text] [Related]  

  • 5. MPL mutation profile in JAK2 mutation-negative patients with myeloproliferative disorders.
    Ma W; Zhang X; Wang X; Zhang Z; Yeh CH; Uyeji J; Albitar M
    Diagn Mol Pathol; 2011 Mar; 20(1):34-9. PubMed ID: 21326037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms.
    Rumi E; Pietra D; Guglielmelli P; Bordoni R; Casetti I; Milanesi C; Sant'Antonio E; Ferretti V; Pancrazzi A; Rotunno G; Severgnini M; Pietrelli A; Astori C; Fugazza E; Pascutto C; Boveri E; Passamonti F; De Bellis G; Vannucchi A; Cazzola M;
    Blood; 2013 May; 121(21):4388-95. PubMed ID: 23575445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The JAK2 46/1 haplotype predisposes to MPL-mutated myeloproliferative neoplasms.
    Jones AV; Campbell PJ; Beer PA; Schnittger S; Vannucchi AM; Zoi K; Percy MJ; McMullin MF; Scott LM; Tapper W; Silver RT; Oscier D; Harrison CN; Grallert H; Kisialiou A; Strike P; Chase AJ; Green AR; Cross NC
    Blood; 2010 Jun; 115(22):4517-23. PubMed ID: 20304805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. JAK2 V617F and MPL W515L/K mutations in Korean patients with essential thrombocythemia.
    Kim HJ; Jang JH; Yoo EH; Kim HJ; Ki CS; Kim JW; Kim SH
    Korean J Lab Med; 2010 Oct; 30(5):474-6. PubMed ID: 20890078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concomitant and noncanonical JAK2 and MPL mutations in JAK2V617F- and MPLW515 L-positive myelofibrosis.
    Schulze S; Stengel R; Jaekel N; Wang SY; Franke GN; Roskos M; Schneider M; Niederwieser D; Al-Ali HK
    Genes Chromosomes Cancer; 2019 Nov; 58(11):747-755. PubMed ID: 31135094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased frequency of co-existing JAK2 exon-12 or MPL exon-10 mutations in patients with low JAK2(V617F) allelic burden.
    Nussenzveig RH; Pham HT; Perkins SL; Prchal JT; Agarwal AM; Salama ME
    Leuk Lymphoma; 2016; 57(6):1429-35. PubMed ID: 26419289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MPL W515L/K mutations in 343 Chinese adults with JAK2V617F mutation-negative chronic myeloproliferative disorders detected by a newly developed RQ-PCR based on TaqMan MGB probes.
    Ruan GR; Jiang B; Li LD; Niu JH; Li JL; Xie M; Qin YZ; Liu YR; Huang XJ; Chen SS
    Hematol Oncol; 2010 Mar; 28(1):33-9. PubMed ID: 19274616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. JAK2 GGCC haplotype in MPL mutated myeloproliferative neoplasms.
    Pietra D; Casetti I; Da Vià MC; Elena C; Milanesi C; Rumi E
    Am J Hematol; 2012 Jul; 87(7):746-7. PubMed ID: 22565617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The analysis of JAK2 and MPL mutations and JAK2 single nucleotide polymorphisms in MPN patients by MassARRAY assay.
    Zhang SJ; Qiu HX; Li JY; Shi JY; Xu W
    Int J Lab Hematol; 2010 Aug; 32(4):381-6. PubMed ID: 20331763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort.
    Beer PA; Campbell PJ; Scott LM; Bench AJ; Erber WN; Bareford D; Wilkins BS; Reilly JT; Hasselbalch HC; Bowman R; Wheatley K; Buck G; Harrison CN; Green AR
    Blood; 2008 Jul; 112(1):141-9. PubMed ID: 18451306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The mutation profile of JAK2, MPL and CALR in Mexican patients with Philadelphia chromosome-negative myeloproliferative neoplasms.
    Labastida-Mercado N; Galindo-Becerra S; Garcés-Eisele J; Colunga-Pedraza P; Guzman-Olvera V; Reyes-Nuñez V; Ruiz-Delgado GJ; Ruiz-Argüelles GJ
    Hematol Oncol Stem Cell Ther; 2015 Mar; 8(1):16-21. PubMed ID: 25637689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Somatic mutations of calreticulin in myeloproliferative neoplasms.
    Klampfl T; Gisslinger H; Harutyunyan AS; Nivarthi H; Rumi E; Milosevic JD; Them NC; Berg T; Gisslinger B; Pietra D; Chen D; Vladimer GI; Bagienski K; Milanesi C; Casetti IC; Sant'Antonio E; Ferretti V; Elena C; Schischlik F; Cleary C; Six M; Schalling M; Schönegger A; Bock C; Malcovati L; Pascutto C; Superti-Furga G; Cazzola M; Kralovics R
    N Engl J Med; 2013 Dec; 369(25):2379-90. PubMed ID: 24325356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MPL W515L mutation in Chinese patients with myeloproliferative diseases.
    Xu W; Li JY; Xia J; Zhang SJ; Fan L; Qiao C
    Leuk Lymphoma; 2008 May; 49(5):955-8. PubMed ID: 18464114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a Targeted Next-Generation Sequencing Assay to Detect Diagnostically Relevant Mutations of JAK2, CALR, and MPL in Myeloproliferative Neoplasms.
    Frawley T; O'Brien CP; Conneally E; Vandenberghe E; Percy M; Langabeer SE; Haslam K
    Genet Test Mol Biomarkers; 2018 Feb; 22(2):98-103. PubMed ID: 29323541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
    Michiels JJ; Berneman Z; Schroyens W; De Raeve H
    Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation analysis between JAK2, MPL, and CALR mutations in patients with myeloproliferative neoplasms of Chinese Uygur and Han nationality and their clinical characteristics.
    Lang T; Nie Y; Wang Z; Huang Q; An L; Wang Y; Wufuer G; Maimaiti A; Fu L; Li Y; Zhang X; Aisimutula A; Wang X; Zhu L; Liu H; Mao M
    J Int Med Res; 2018 Nov; 46(11):4650-4659. PubMed ID: 30084272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.